PE/VC investors
Private Equity (PE) and Venture Capital (VC) investors are the catalysts of innovation and growth in the business world. PE firms primarily target established companies, seeking to optimize operations and unlock value through strategic investments and management expertise. They focus on long-term growth and profitability, often preparing businesses for a future sale or IPO. VC investors, by contrast, are the adventurers of finance, injecting capital into high-potential startups and early-stage companies. They embrace risk for the possibility of outsized returns, often becoming invaluable advisors. Both investor types not only bring capital but also strategic guidance, industry connections, and market insights, propelling their portfolio companies towards success.
Investors (6,250)
Investor
Description
More information
Argosy
Argosy is an independent private equity and advisory firm based in the Philippines with strategic partners and relationships in Singapore, Indonesia, Thailand, Malaysia, India and Japan. Argosy has advised over 50 multinational companies and international institutional investors for the Philippines. It also has the unique expertise of branching outside of the country, with several of its local invested countries expanding to India, Indonesia and as far as South America.
Argosy Partners Ltd.
Argosy Partners is a private equity firm based in Toronto, Canada. We combine our capital with that of a number of successful entrepreneurs and institutional investors to deliver effective financial solutions for small and medium-sized businesses. Learn more about our specialized private equity funds and our current company investments.
Aria
![Aria]()
ARIA to fundusz growth, inwestujący w spółki technologiczne z Europy Centralnej. Skupiamy się na zespołach, które przeszły pierwszą próbę rynkową i posiadają zweryfikowany model biznesowy. Wierzymy, że efektywna współpraca między założycielami biznesów a funduszem może przynieść ponadprzeciętne rezultaty. W związku z tym aktywnie wspieramy nasze spółki w szerokim spektrum zagadnień związanych z dalszym rozwojem biznesu. --- ARIA is a growth fund investing in tech scale ups from the Central Europe. We focus on early growth, post-product, high-tech scale ups that are developing unique technologies. We believe that an effective cooperation between business founders and the fund can bring extraordinary results. Therefore, we actively support our companies in a wide range of issues related to further business growth.
Ariol Capital
Ariol Capital is a private equity firm that makes long-term investments in established packaging companies in the middle market. Our company is formed by a group of successful business managers and investors who are passionate about building and growing healthy companies.
<br />
<br />
Ariol Capital provides not only capital but also management and operations experience to support long-term value creation. We take an active role in managing the day-to-day operations of the companies in which we invest in. Following an investment, we assume full-time management positions alongside the current management team, allowing the owner/operator to gain additional management talent or to transition out of a daily operating role if desired.
<br />
Aristos Ventures
Aristos Ventures is a venture capital firm that invests in highly capital-efficient technology companies in Texas.
<br />
<br />
Aristos Ventures focuses on IT-related sectors: Mobile enrichment, Web-based applications and information services, and SaaS/cloud infrastructure. These sectors are expected to generate substantial growth as the desktop internet economy inevitably goes mobile, providing a powerful inflection point for technology infrastructure built over 30 years.
Arix Bioscience
![Arix Bioscience]()
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.
Arjun Infrastructure Partners Ltd.
Arjun Infrastructure Partners is an independent infrastructure asset management company that was founded in 2015. We invest and manage capital on behalf of like-minded institutional investors, delivering attractive risk-adjusted returns within a long-term alliance framework.
<br />
<br />
We currently manage $2.3 billion of capital across 12 investments or investment platforms on behalf of institutional investors.
<br />
<br />
<br />
<br />
Arjun offers a true partnership approach to institutional investors to access direct infrastructure investments, working with them as an extension of their own team.
<br />
<br />
<br />
With eighteen professionals and nine industry partners, our team has extensive operational and financial experience in utilities, energy & renewables and transportation. We have attracted highly talented senior industry professionals who share the ambition of building a fully aligned long-term partnership with our clients.
<br />
<br />
<br />
<br />
Arkea Capital
![Arkea Capital]()
Arkéa Capital accompagne comme actionnaire minoritaire les entreprises à toutes les étapes de développement, depuis la start-up jusqu’à l’ETI, en maintenant l’indépendance des centres de décisions. Nous envisageons la réussite entrepreneuriale selon des critères de performance globale : économique, financière, écologique et humaine. Notre engagement s'inscrit dans la durée, selon une logique de partenariat reposant sur une confiance et une transparence réciproques.
Au sein du groupe Arkéa, nous gérons un portefeuille d'une centaine de participations, avec près d’1,1 milliard d’euros d’actifs sous gestion, depuis Brest, Nantes, Rennes, Bordeaux, Paris, Strasbourg et Lyon.
Arkin Holdings
![Arkin Holdings]()
FAMILY HISTORY
In 1961 Mr. Ziama Arkin founded Agis as the certified Israeli pharmaceutical importer for a number of foreign pharma companies. After the death of Mr. Ziama Arkin in 1972, his 19 year old son, Mori, took the lead, while he was serving in the IDF and completing a degree in Psychology.
In 1994, Agis purchased Clay Park and gained with it, control over its first production facility. A new era of Agis drug development and production had begun. Under Mori Arkin, who remained the principal shareholder and chairman of the board, Agis (1983) Ltd. grew to become one of the biggest leaders in the dermatological generic space in the US. In 2005 Perrigo (PRGO) purchased Agis in an $818M transaction.
Arkin Holdings is dedicated to empowering companies that create breakthrough pharma, biotech and medical device technologies. Our synergistic healthcare investments are dedicated to creating innovations that benefit humanity and enhance medical care.
We offer extensive experience, with a track record of successful healthcare investments. Experts in the dynamic world of healthcare development, we provide the know-how and close accompaniment that helps our portfolio investments achieve substantial value and growth.
Arkley Brinc VC
![Arkley Brinc VC]()
Arkley Brinc provides venture capital for early-stage startups throughout Poland and Europe, with a focus on Deep Tech, IoT and hardware-related sectors. In addition to funding, we offer over a decade of first-hand experience in business and product development, and a network that reaches deep into Silicon Valley and the Greater Bay region in China.
